<mods:mods xsi:schemaLocation="http://www.loc.gov/mods/v3 http://www.loc.gov/standards/mods/v3/mods-3-3.xsd" version="3.3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:mods="http://www.loc.gov/mods/v3"><mods:titleInfo><mods:title>INNOVATIVE THERAPEUTIC STRATEGIES FOR MANAGING POST CASTRATION SYNDROME AFTER OVARIAN HYPERSTIMULATION</mods:title></mods:titleInfo><mods:name type="personal"><mods:namePart type="given">Soxiba</mods:namePart><mods:namePart type="family">Narkulova</mods:namePart><mods:role><mods:roleTerm type="text">author</mods:roleTerm></mods:role></mods:name><mods:name type="personal"><mods:namePart type="given">Zarina</mods:namePart><mods:namePart type="family">Xudoyberdiyeva</mods:namePart><mods:role><mods:roleTerm type="text">author</mods:roleTerm></mods:role></mods:name><mods:abstract>Definition and clinical importance Post‑castration syndrome (PCS) can develop after oocyte retrieval and luteal phase; severe ovarian hyperstimulation syndrome (OHSS) manifests as ascites, electrolyte imbalance, ovarian enlargement, and systemic signs. Although PCS is relatively rare, complications can be life-threatening and compromise IVF outcomes.</mods:abstract><mods:originInfo><mods:dateIssued encoding="iso8601">2025-06-08</mods:dateIssued></mods:originInfo><mods:originInfo><mods:publisher>Research Science and Innovation house</mods:publisher></mods:originInfo><mods:genre>Maqola</mods:genre></mods:mods>